Hormone Receptor-Positive Breast Cancer About 80% of allbreastcancers are “ER-positive.” That means thecancercells grow in response to the hormone estrogen. About 65% of these are also “PR-positive.” They grow in response to another hormone, progesterone. ...
Kerenyi, L. M. (2007). A structural analysis of the impact of breast cancer on positive and negative domains of quality of life. Unpublished doctoral dissertation, State University of New York at Buffalo, Buffalo, NY.Kerenyi LM (2008) A structural analysis of the impact of breast cancer on...
[translate] aAndrogen receptor-positive triple negative breast cancer: a unique breast cancer subtype. 雄激素感受器阳性三倍数否定乳腺癌:独特的乳腺癌子型。[translate]
Immunotherapy for HER-2 positive breast cancer Immunotherapy is a developing treatment for advanced breast cancer. Immunotherapy has clinical significance for the treatment of triple-negative breast can... Tingting Yang,Lihua Kang,Dan Li,... - Frontiers in Oncology 被引量: 0发表: 2023年 加载更多...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...
Purpose The aim of the study was to explore the role of positive and negative aspects of well-being in a breast reconstruction decision, described in terms of the transtheoretical model of change (TTM). Methods The study comprised 216 women after total mastectomy in the cross-sectional design....
This retrospective study included 278 female patients diagnosed and operated for breast cancer. Patients were grouped into 2 groups according to the expression of Ki67 to those with positive and those with negative expression. Both groups were compared for differences. Results The mean age was 48.61...
Triple negative breast cancer (TNBC) is a deadly form of breast cancer due to the development of resistance to chemotherapy affecting over 30% of patients. New therapeutics and companion biomarkers are urgently needed. Recognizing the elevated expression of glucose transporter 1 (GLUT1, encoded bySL...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drug...